Objective: This study aimed to evaluate the association between anxiety and receipt of treatments for esophageal cancer.
| INTRODUCTION
Esophageal cancer (EC) is the eighth most common cancer in the world, with over 450 000 incident cases diagnosed each year. 1 Over the past decade, the prevalence of EC has increased worldwide. [2] [3] [4] [5] [6] Treatments for EC include surgery, endoscopic therapies, radiotherapy, or chemotherapy used alone or in combination for different stages. Evidence revealed that cancer treatments can prolong the overall survival at any stages of EC. 7, 8 Delayed or refusal of treatments Dr. Chuan-Pin Lee and Dr. Shu-I Wu contributed equally to this work.
may cause a poor prognosis. 7 However, previous studies showed that only one third of patients were presented as resectable at initial diagnosis, 9 and more than two third were diagnosed in advanced stage. 9 Patients' delay or refusal for cancer treatments might underlie this and might result in somewhat preventable excess mortality. 10 Literature has explored barriers for receiving cancer treatments.
Shayeb et al described that patient factors associated with treatment refusal might include underlying physical comorbidities, such as liver cirrhosis or chronic renal failure, concerns about adverse effects, poor support system, financial situation, transportation difficulty, or use of alternative medicine. 11 Psychiatric comorbidities, including anxiety and depression, had shown to impede the timely diagnosis and subsequent therapeutic management. 12 However, the association between psychiatric comorbidities and the volition of treatments among patients with EC has not been extensively studied in larger samples.
Because remedial of psychiatric problems may help change patients' perceptions about receiving cancer treatment, 13 to find out the effects of anxiety disorder on the receipt of treatments in EC patients becomes an important issue. Hence, we carried out this nationwide population-based retrospective cohort study to determine whether patients of EC that had anxiety disorder diagnosed before cancer are less likely to receive relevant cancer managements or not. 
| PATIENTS AND METHODS

| Data sources
| Study population
The flowchart was shown in Figure 1 . Using the discharge codes (ICD- included patients with advanced stages (those withdraw from the registry 2 months after diagnosis; a proxy for mortality), (2) those with diagnoses of metastatic cancer at initial presentation, and (3) the analysis that excluded these patients with advanced stages. The statistical significance of associations was assessed by using P value <.05 or a 95% confidence interval (CI). All of the analyses were performed using SAS version 9.4.
| RESULTS
During the study period, a total of 10 537 patients with EC were enrolled. Mean age of these patients was 60.4 years. The demographic data of our study participants with EC were shown in Table 1 . The mean duration from EC diagnosis to treatment receipt was 2.5 months.
Of the 10 537 patients, 732 patients (6.9%) had anxiety disorder before the diagnosis of EC (Table 1) . Competing risk regression in Table 2 showed that having anxiety disorder was positively associated with the receipt of anticancer treatments (HR 1.12, 95% CI 1.03-1. Subanalysis comparing the chances of receiving anticancer therapy between people with and without anxiety disorder stratified by covariates was further described in 
| DISCUSSION
To our knowledge, this is the first study that was able to explore the effects of anxiety on the treatment receipt of EC using a nationwide, seeking. 23 The identification, psychoeducation, and appropriate management of patients' anxiety may provide an oppotune window to encourage them receive cancer treatments. 18, 24 In this study, we have also found that old age and comorbidities of chronic renal failure or liver cirrhosis were risk factors for not receiving regardless of the appropriateness of physical condition, psychosocial supports or psychoeducation should be provided to avoid overtreatment.
Our study showed that female patients with EC were less likely to receive treatments than men. Van Kleffens et al studied 30 cancer patients who refused treatment in the Netherlands and also found women predominance. 25 They suggested that the reason men were more likely to receive anticancer treatment might be attributable to the male family role that emphasizes on staying healthy in order to fulfill the financial responsibility to the family.
Our result that patients with the highest income level were more likely to receive anticancer treatment than those with no income was different from what Thien et al have described that no significant differences were found in anticancer treatment between the highest and lowest income groups. 26 
| Strengths and limitations
The present study had many important methodological advantages.
Our information was collected from a population-based database that selection and recall bias were able to be minimized. We were able to evaluate possible risk factors or adjust for covariates that might affect patients' receipts of anticancer therapy. Key limitations influencing interpretations and inferences of our findings include, first, information regarding other risk factors affecting the receipt of cancer treatment was lacking; for example, information regarding disease staging, pain, patients' refusal or were not offered of treatments, or other barriers, such as financial concerns, or being unfit for the treatment, 30 was not available in the NHIRD. However, we tried to identify those with diagnoses of metastatic cancer and those withdraw from the registry (a proxy for mortality) as having advanced stages at initial presentation. Similar results were still found from sensitivity analyses. Second, we cannot assure whether patients received self-paid anticancer treatments or not, although it is a rare condition in Taiwan under the near-universal health-care insurance policy. Third, clinical diagnoses obtained from the database were given for insurance claim and not for research purposes and therefore might not be fully met the research criteria. Also, we were unable to investigate whether levels of anxiety (mild or severe) would be associated with delayed treatment seeking or not. However, using such clinical database still has the compensating advantage of the exploration in a real-world setting. Fourth, we were unable to confirm whether subjects were free of psychiatric disorders before cancer if their illness was not severe enough to attract clinical attention. A bias of underestimation might occur.
| Clinical implications
In conclusion, reasons why EC patients with preexisting anxiety disorder had higher treatment receipt than those without anxiety disorder may vary. First-line clinicians should be aware that patients' psychiatric conditions may be influential to the decision making process for the receipt of cancer treatment. Future studies exploring factors affecting such process among cancer patients with anxiety in order to help other unwilling patients to consider anticancer treatments and the incorporation of healthy literacy may be needed.
